Sipavibart
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | SARS-CoV-2 |
| Clinical data | |
| Trade names | Kavigale |
| Other names | AZD-3152 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised.[3] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[3][5]
Sipavibart was authorized for medical use in the European Union in January 2025.[3][4]
- ^ "Summary Basis of Decision for Kavigale". Drug and Health Products Portal. 5 June 2025. Retrieved 22 June 2025.
- ^ "Register of Innovative Drugs". Health Canada. 3 November 2006. Retrieved 17 April 2025.
- ^ a b c d Cite error: The named reference
Kavigale EPARwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Kavigale PIwas invoked but never defined (see the help page). - ^ "Sipavibart (Code C200075)". NCI Thesaurus. 25 November 2024. Archived from the original on 22 December 2024. Retrieved 16 December 2024.